The entire population is firstly screened for biomarker status and all individuals enter the trial.
Alternative names: Mixture designs, Combination of trial designs, hybrid biomarker designs
Details
Utility
Hybrid designs can be used when there is compelling prior evidence which shows detrimental effect of the experimental treatment for a specific biomarker-defined subgroup (i.e., biomarker-negative subgroup) or some indication of its possible excessive toxicity in that subgroup, thus making it unethical to randomize the patients within this population to the experimental treatment.
Methodology
- Similar to the enrichment designs, hybrid designs are powered to identify treatment effect only in the biomarker-defined subgroup which is randomly assigned to the experimental or control treatment groups.
- These designs are a combination of an enrichment design where we randomize patients to either the experimental or the control treatment group and single-arm designs in biomarker-negative patients.
Sample size Formula
The same formula used for the required number of patients or events for the enrichment designs can be used for hybrid designs.
Statistical/Practical considerations
Advantages
- The feasibility of a prognostic biomarker can be tested.
- Allow for better risk assessment and improved individualized treatment since it assigns patients to treatments based on risk assessment scores instead of their biomarker status (biomarker-positive and biomarker-negative patients).
Limitations
- None found
Key references
- George, S.L. Statistical issues in translational cancer research. Clin. Cancer Res. 2008, 14, 5954–5958. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.J.; Lu, T.-P.; Chen, D.-T.; Wang, S.-J. Biomarker adaptive designs in clinical trials. Transl. Cancer Res. 2014, 3, 279–292. [Google Scholar]
- Gosho, M.; Nagashima, K.; Sato, Y. Study designs and statistical analyses for biomarker research. Sensors 2012, 12, 8966–8986. [Google Scholar] [CrossRef] [PubMed]
- Buyse, M.; Sargent, D.J.; Grothey, A.; Matheson, A.; de Gramont, A. Biomarkers and surrogate end points—The challenge of statistical validation. Nat. Rev. Clin. Oncol. 2010, 7, 309–317. [Google Scholar] [CrossRef] [PubMed]
- Mandrekar, S.J.; Sargent, D.J. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J. Clin. Oncol. 2009, 27, 4027–4034. [Google Scholar] [CrossRef] [PubMed]
- Mandrekar, S.J.; Sargent, D.J. Clinical trial designs for predictive biomarker validation: One size does not fit all. J. Biopharm. Stat. 2009, 19, 530–542. [Google Scholar] [CrossRef] [PubMed]
- Tajik, P.; Zwinderman, A.H.; Mol, B.W.; Bossuyt, P.M. Trial designs for personalizing cancer care: A systematic review and classification. Clin. Cancer Res. 2013, 19, 4578–4588. [Google Scholar] [CrossRef] [PubMed]
- Van Schaeybroeck, S.; Allen, W.L.; Turkington, R.C.; Johnston, P.G. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat. Rev. Clin. Oncol. 2011, 8, 222–232. [Google Scholar] [CrossRef] [PubMed]
- Sparano, J.A.; Paik, S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 2008, 26, 721–728. [Google Scholar] [CrossRef] [PubMed]
- Sato, Y.; Laird, N.M.; Yoshida, T. Biostatistic tools in pharmacogenomics—Advances, challenges, potential. Curr. Pharm. Des. 2010, 16, 2232–2240. [Google Scholar] [CrossRef] [PubMed]
- Collette, L.; Bogaerts, J.; Suciu, S.; Fortpied, C.; Gorlia, T.; Coens, C.; Mauer, M.; Hasan, B.; Collette, S.; Ouali, M.; et al. Statistical methodology for personalized medicine: New developments at EORTC headquarters since the turn of the 21st century. Eur. J. Cancer Suppl. 2012, 10, 13. [Google Scholar] [CrossRef]
- Lin, J.-A.; He, P. Reinventing clinical trials: A review of innovative biomarker trial designs in cancer therapies. Br. Med. Bull. 2015, 114, 17–27. [Google Scholar] [CrossRef] [PubMed]
- European Medicines Agency. Reflection Paper on Methodological Issues Associated with Pharmacogenomic Biomarkers in Relation to Clinical Development and Patient Selection. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500108672.pdf (accessed on 10 October 2015).
- Wang, S.-J.; O’Neill, R.T.; Hung, H.M.J. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subgroup. Pharm. Stat. 2007, 6, 227–244. [Google Scholar] [CrossRef] [PubMed]